Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 12 studies | 40% ± 19% | |
ciliated cell | 12 studies | 36% ± 17% | |
basal cell | 10 studies | 30% ± 20% | |
endothelial cell | 10 studies | 23% ± 8% | |
fibroblast | 10 studies | 27% ± 9% | |
adipocyte | 10 studies | 26% ± 6% | |
epithelial cell of proximal tubule | 9 studies | 41% ± 14% | |
pericyte | 8 studies | 20% ± 4% | |
enterocyte | 7 studies | 44% ± 16% | |
glutamatergic neuron | 7 studies | 40% ± 26% | |
hepatocyte | 6 studies | 65% ± 20% | |
progenitor cell | 5 studies | 21% ± 8% | |
connective tissue cell | 5 studies | 24% ± 10% | |
astrocyte | 5 studies | 22% ± 7% | |
kidney connecting tubule epithelial cell | 4 studies | 55% ± 25% | |
kidney distal convoluted tubule epithelial cell | 4 studies | 47% ± 14% | |
renal alpha-intercalated cell | 4 studies | 36% ± 11% | |
transit amplifying cell | 4 studies | 19% ± 2% | |
abnormal cell | 4 studies | 24% ± 10% | |
macrophage | 4 studies | 18% ± 2% | |
GABAergic neuron | 4 studies | 50% ± 17% | |
secretory cell | 4 studies | 34% ± 26% | |
neuron | 4 studies | 35% ± 16% | |
oligodendrocyte | 4 studies | 23% ± 6% | |
kidney loop of Henle epithelial cell | 3 studies | 21% ± 2% | |
myofibroblast cell | 3 studies | 16% ± 1% | |
intestinal crypt stem cell | 3 studies | 25% ± 7% | |
smooth muscle cell | 3 studies | 18% ± 2% | |
club cell | 3 studies | 24% ± 10% | |
type II pneumocyte | 3 studies | 21% ± 3% | |
retinal cone cell | 3 studies | 22% ± 4% | |
oligodendrocyte precursor cell | 3 studies | 24% ± 4% | |
goblet cell | 3 studies | 18% ± 2% | |
interneuron | 3 studies | 53% ± 20% | |
renal principal cell | 3 studies | 51% ± 27% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2376.61 | 245 / 245 | 99% | 100.33 | 495 / 502 |
kidney | 100% | 6914.87 | 89 / 89 | 98% | 74.60 | 884 / 901 |
ovary | 100% | 1423.45 | 180 / 180 | 96% | 36.21 | 411 / 430 |
esophagus | 100% | 3458.91 | 1444 / 1445 | 95% | 60.13 | 174 / 183 |
breast | 100% | 2379.90 | 459 / 459 | 94% | 40.68 | 1053 / 1118 |
liver | 100% | 16118.89 | 226 / 226 | 94% | 198.63 | 381 / 406 |
uterus | 100% | 1737.17 | 170 / 170 | 94% | 53.18 | 430 / 459 |
thymus | 100% | 1577.78 | 652 / 653 | 94% | 34.94 | 567 / 605 |
lung | 99% | 1545.03 | 570 / 578 | 94% | 85.09 | 1085 / 1155 |
intestine | 100% | 3268.95 | 964 / 966 | 92% | 28.14 | 484 / 527 |
bladder | 100% | 4394.95 | 21 / 21 | 91% | 63.30 | 460 / 504 |
skin | 100% | 2770.60 | 1808 / 1809 | 90% | 28.41 | 423 / 472 |
stomach | 100% | 5090.77 | 358 / 359 | 85% | 24.66 | 244 / 286 |
pancreas | 81% | 607.73 | 266 / 328 | 95% | 39.97 | 169 / 178 |
adrenal gland | 100% | 5557.85 | 258 / 258 | 71% | 22.63 | 164 / 230 |
brain | 86% | 873.66 | 2281 / 2642 | 68% | 15.77 | 482 / 705 |
adipose | 100% | 2386.34 | 1204 / 1204 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.55 | 1 / 1 |
blood vessel | 99% | 1322.73 | 1322 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 27.66 | 77 / 80 |
tonsil | 0% | 0 | 0 / 0 | 96% | 40.44 | 43 / 45 |
heart | 92% | 1214.91 | 789 / 861 | 0% | 0 | 0 / 0 |
spleen | 67% | 449.43 | 162 / 241 | 0% | 0 | 0 / 0 |
muscle | 49% | 324.29 | 393 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 17% | 195.52 | 162 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.41 | 1 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006691 | Biological process | leukotriene metabolic process |
GO_2001302 | Biological process | lipoxin A4 metabolic process |
GO_0036102 | Biological process | leukotriene B4 metabolic process |
GO_0006693 | Biological process | prostaglandin metabolic process |
GO_0005737 | Cellular component | cytoplasm |
GO_0070062 | Cellular component | extracellular exosome |
GO_0036185 | Molecular function | 13-lipoxin reductase activity |
GO_0036132 | Molecular function | 13-prostaglandin reductase activity |
GO_0035798 | Molecular function | 2-alkenal reductase (NADPH) activity |
GO_0005515 | Molecular function | protein binding |
GO_0047522 | Molecular function | 15-oxoprostaglandin 13-oxidase activity |
GO_0097257 | Molecular function | leukotriene B4 12-hydroxy dehydrogenase activity |
Gene name | PTGR1 |
Protein name | 15-oxoprostaglandin 13-reductase (EC 1.3.1.48) (15-oxoprostaglandin 13-reductase) Prostaglandin reductase 1 (EC 1.3.1.48) (EC 1.3.1.74) (15-oxoprostaglandin 13-reductase) (Dithiolethione-inducible gene 1 protein) (Leukotriene B4 12-hydroxydehydrogenase) (NAD(P)H-dependent alkenal/one oxidoreductase) Prostaglandin reductase 1 (PRG-1) (15-oxoprostaglandin 13-reductase) (EC 1.3.1.48) (Dithiolethione-inducible gene 1 protein) (D3T-inducible gene 1 protein) (DIG-1) (Leukotriene B4 12-hydroxydehydrogenase) (NAD(P)H-dependent alkenal/one oxidoreductase) (EC 1.3.1.74) |
Synonyms | LTB4DH |
Description | FUNCTION: NAD(P)H-dependent oxidoreductase involved in metabolic inactivation of pro- and anti-inflammatory eicosanoids: prostaglandins (PG), leukotrienes (LT) and lipoxins (LX) . Catalyzes with high efficiency the reduction of the 13,14 double bond of 15-oxoPGs, including 15-oxo-PGE1, 15-oxo-PGE2, 15-oxo-PGF1-alpha and 15-oxo-PGF2-alpha . Catalyzes with lower efficiency the oxidation of the hydroxyl group at C12 of LTB4 and its derivatives, converting them into biologically less active 12-oxo-LTB4 metabolites (By similarity). Reduces 15-oxo-LXA4 to 13,14 dihydro-15-oxo-LXA4, enhancing neutrophil recruitment at the inflammatory site (By similarity). May play a role in metabolic detoxification of alkenals and ketones. Reduces alpha,beta-unsaturated alkenals and ketones, particularly those with medium-chain length, showing highest affinity toward (2E)-decenal and (3E)-3-nonen-2-one . May inactivate 4-hydroxy-2-nonenal, a cytotoxic lipid constituent of oxidized low-density lipoprotein particles (By similarity). . |
Accessions | Q5JVP2 ENST00000374324.5 F2Z3J9 ENST00000407693.7 [Q14914-1] ENST00000309195.9 [Q14914-1] Q14914 ENST00000538962.7 [Q14914-2] ENST00000422125.1 F6XGT7 ENST00000466771.6 |